Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Arteriosclerosis

ClinicalTrials.gov lists 7,690 trials for Arteriosclerosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 126.

MeSH D001161 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 406 Phase 2/3 Phase 2/3 107 Phase 3 Phase 3 469 Phase 4 Phase 4 900 Not applicable Not applicable 2,758 Observational Observational 2,693 Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 406 Phase 2/3 Phase 2/3 107 Phase 3 Phase 3 469 Phase 4 Phase 4 900 Not applicable Not applicable 2,758 Observational Observational 2,693

Trials per phase (log scale)

1 more section with rows

153 of the 7,690 trials are tagged with Arteriosclerosis itself; the rest are tagged with a narrower condition beneath it.

Get the Arteriosclerosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Arteriosclerosis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 378

1990: 6 trials (Observational 4, Phase 3 1, Phase 2 1) 1991: 8 trials (Observational 7, Phase 4 1) 1992: 9 trials (Observational 9) 1993: 6 trials (Observational 3, Phase 4 1, Phase 2 1, Phase 1 1) 1994: 8 trials (Observational 6, Phase 3 1, Phase 2/3 1) 1995: 14 trials (Observational 9, Not applicable 2, Phase 3 2, Phase 2 1) 1996: 16 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 2, Phase 2/3 1) 1997: 13 trials (Observational 5, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 2) 1998: 14 trials (Observational 7, Not applicable 2, Phase 4 1, Phase 3 4) 1999: 22 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2000: 52 trials (Observational 26, Not applicable 10, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 3, Phase 1/2 2, Phase 1 1) 2001: 52 trials (Observational 25, Not applicable 3, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 9, Phase 1 1) 2002: 76 trials (Observational 16, Not applicable 16, Phase 4 14, Phase 3 12, Phase 2/3 3, Phase 2 9, Phase 1/2 2, Phase 1 4) 2003: 118 trials (Observational 35, Not applicable 12, Phase 4 20, Phase 3 30, Phase 2/3 3, Phase 2 8, Phase 1/2 5, Phase 1 5) 2004: 124 trials (Observational 31, Not applicable 18, Phase 4 28, Phase 3 20, Phase 2/3 8, Phase 2 10, Phase 1/2 3, Phase 1 6) 2005: 155 trials (Observational 34, Not applicable 33, Phase 4 34, Phase 3 25, Phase 2/3 3, Phase 2 19, Phase 1/2 2, Phase 1 5) 2006: 223 trials (Observational 60, Not applicable 43, Phase 4 50, Phase 3 21, Phase 2/3 2, Phase 2 26, Phase 1/2 4, Phase 1 17) 2007: 242 trials (Observational 68, Not applicable 57, Phase 4 40, Phase 3 22, Phase 2/3 6, Phase 2 22, Phase 1/2 5, Phase 1 22) 2008: 278 trials (Observational 89, Not applicable 72, Phase 4 51, Phase 3 19, Phase 2/3 9, Phase 2 20, Phase 1/2 6, Phase 1 12) 2009: 301 trials (Observational 91, Not applicable 79, Phase 4 56, Phase 3 27, Phase 2/3 8, Phase 2 18, Phase 1/2 11, Phase 1 11) 2010: 312 trials (Observational 116, Not applicable 82, Phase 4 58, Phase 3 15, Phase 2/3 5, Phase 2 16, Phase 1/2 7, Phase 1 13) 2011: 314 trials (Observational 94, Not applicable 98, Phase 4 46, Phase 3 30, Phase 2/3 7, Phase 2 25, Phase 1/2 8, Phase 1 6) 2012: 308 trials (Observational 103, Not applicable 90, Phase 4 51, Phase 3 19, Phase 2/3 3, Phase 2 25, Phase 1/2 3, Phase 1 14) 2013: 315 trials (Observational 97, Not applicable 108, Phase 4 41, Phase 3 24, Phase 2/3 7, Phase 2 24, Phase 1/2 2, Phase 1 12) 2014: 341 trials (Observational 122, Not applicable 128, Phase 4 50, Phase 3 9, Phase 2/3 3, Phase 2 17, Phase 1/2 4, Phase 1 8) 2015: 333 trials (Other 1, Observational 98, Not applicable 131, Phase 4 44, Phase 3 19, Phase 2/3 6, Phase 2 18, Phase 1/2 4, Phase 1 12) 2016: 342 trials (Observational 122, Not applicable 149, Phase 4 34, Phase 3 11, Phase 2/3 2, Phase 2 14, Phase 1/2 4, Phase 1 6) 2017: 359 trials (Observational 137, Not applicable 145, Phase 4 33, Phase 3 14, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 12) 2018: 369 trials (Observational 123, Not applicable 170, Phase 4 33, Phase 3 15, Phase 2/3 3, Phase 2 9, Phase 1/2 3, Phase 1 13) 2019: 339 trials (Observational 138, Not applicable 135, Phase 4 28, Phase 3 12, Phase 2/3 4, Phase 2 11, Phase 1/2 3, Phase 1 8) 2020: 359 trials (Observational 154, Not applicable 142, Phase 4 28, Phase 3 11, Phase 2/3 2, Phase 2 8, Phase 1/2 6, Phase 1 8) 2021: 378 trials (Observational 144, Not applicable 169, Phase 4 25, Phase 3 14, Phase 2/3 2, Phase 2 13, Phase 1/2 2, Phase 1 9) 2022: 378 trials (Observational 144, Not applicable 183, Phase 4 18, Phase 3 11, Phase 2 13, Phase 1 9) 2023: 376 trials (Observational 142, Not applicable 182, Phase 4 31, Phase 3 9, Phase 2/3 2, Phase 2 3, Phase 1/2 3, Phase 1 4) 2024: 374 trials (Observational 150, Not applicable 163, Phase 4 22, Phase 3 12, Phase 2/3 4, Phase 2 12, Phase 1/2 2, Phase 1 9) 2025: 342 trials (Observational 128, Not applicable 151, Phase 4 26, Phase 3 15, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 9)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 335
2025 342
2024 374
2023 376
2022 378
2021 378
2020 359
2019 339
2018 369
2017 359

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 390 trials starting in 2026 and about 360 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 535 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 4,509 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Arteriosclerosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 246
Phase 1/2 102
Phase 2 406
Phase 2/3 107
Phase 3 469
Phase 4 900
Not applicable 2,758
Observational 2,693
Expanded access 9

How many Arteriosclerosis trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 327
Recruiting 786
Enrolling by invitation 53
Active, not recruiting 308
Available 2

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Arteriosclerosis trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 126
Abbott Medical Devices 97
Boston Scientific Corporation 61
China National Center for Cardiovascular Diseases 58
Cordis US Corp. 48

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Arteriosclerosis? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 73
ROSUVASTATIN 57
Ezetimibe 35
SIMVASTATIN 29
Cilostazol 29

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Clopidogrel 75 151
EC Aspirin 119
Ticagrelor (Brilique) 90 95
Prasugel 46
Colchicines 34

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Arteriosclerosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Surgical and medical procedures 12,403 9
Cardiac disorders 9,608 9
Angina pectoris 6,743 120
Angina unstable 5,520 97
Infections and infestations 5,254 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Arteriosclerosis? (1,032)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Accelerated Vascular Aging as a Possible Mechanism of Troponin I Release in the Absence of Clinically Manifested Myocardial Injury. Journal of the American Heart Association 2025 Yes
Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery Occlusion: The CMOSS Randomized Clinical Trial. JAMA 2023 Yes
Association between multi-site atherosclerotic plaques and systemic arteriosclerosis: results from the BEST study (Beijing Vascular Disease Patients Evaluation Study). Cardiovascular ultrasound 2020 Yes
Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet (London, England) 2020 Yes
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes, obesity & metabolism 2015 Yes

Showing 5 of 1,032 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages